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THERAPEUTICAL EVALUATION OF DIFFERENT DOSE REGIMENS OF PRAZIOUANTEL IN
SCHISTOSOMIASIS MANSONI. BASED ON THE OUANTITATIVE OOGRAM TECHNIOUE.III
Aloísio Sales ¿la CUNHA (2), J. Rom€u CANçADO (2) & cetúlio Leonel at€ REZENDE (3)
A clinical trial involving 80 pâtients of both sexes, from âges 15 to 5b, with
chronic intestinal or hepatointestinal schistosomiasis mansoni, was carried out to
evaluate the therapeuticâÌ efncacy of different dose regimens ofpraziquantel.
. The patients were randomly âllocated into four groups with an equal number
of cases and were then treated with one of the following dosâges: 60 mg/kg for
1 day; 60 mg/kg dâily for 2 days; 60 mg/kg daily for 3 days; and 30 mg/kg daily
for 6 days.
The assessment of pansitological cu¡e wâs based on the quantitative oogram
technique through rectal mucosa biopsies v¿hich were undertaken plior to, âs vt ell
as, 1,2,4 and 6 months post-treatment. Concuûently, stool examinations according
to the qualitative Hofünai, Pons & Janer (HPJ) and the quantitative Kato-Katz
(K K) methods were also performed.
The best tolerability was observed with 30 mg/kg daily for 6 days whereas the
highest inÊidence of side-effects (mainly dizziness and nausea) was found with 60
mg/kg daily for 3 days. No serious âdverse d.rug reâction has occurred_
The achieved cure rates were: 25Eo wit}] 60 mg/kg for 1 dayi 60q. with 60 mg/kg
daily fo¡ 2 dàysi 89.5Eo with 60 mg/kg daily for 3 days; and gOEa wil}J 30 mg/kg
daily for 6 days. At the same time there has been a downfall of 64Ea,73Eo. BlEø and,
84% respectively, in the median number ofviable S. mansoni ova pe¡ gram oftissue.
Thus, a very clear direct correlation between dose and effect could be seen.
The corresponding cure rates âccording to stool examinations by HpJ were
399a,809a, l0Ù9a and 95%; by K-K 89Eo, 100Eo, 1007o and I00Z¿. This discrepahcy
in results âmongst the three parasitological methods is certainlidue to theùunequal
âccuracy. In fact, when the number of viâble eggs per gram of tissire feU below
5,000 the difference in the percentage of fâlse negative hndings between HpJ (28%)
and K-K (80%) became significative. When this number dropped to less thân 2,000
the percentage of false negative results obtâined with HpJ (492¿) turned signifrcant
in relation to the oogram as well.
In conclusion, it has been proven thât praziquantel is a highly efncacious agent
against S, mansoni infections, If âdministered at a total dose of 180 mg/kg divided
into either 3 or 6 days, it yields a 907o cure tate. possibly, one Could reac¡' IOO%
by increâsing the totâl dose to 240 mg/kg. Furthermore, it wâs conhrmed that the
quântitative oogram technique is the most reliable parâsitologicâl method when
evaluating the efficacy of new dn¡gs in schistosomiasis mansoni.
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Praziquantel, an isoquinoline-pyrazino deri-
vative, is a broâd spectrum antiheìminthic
agent36 which has Þroven in experimentâl stu-
dies to be a remarkable active compound
against all schistosome species pathogenic to
man13 34 as {6, including Scbistosoma mansoni
strains resistânt to oxamniquiner3 ¡{. It has also
shown to bear a quite sâfe toxicological p¡ofitel?-
In humån schistosomiasis mansoni, using
single oral doses ftom 40 to 60 mg/kg BWT, cure
rates higher than 807¿ have been reportedin Bra-
zil in accordance with parasitological assess-
ments by Kato-Katz stool exãni¡âtionsro 26 40 43,
fnclusively, double-blind trials applying the
same parasitological methodology to compare
the efñcacy of praziquantel and oxamniquine
failed to disclose significânt difrerences between
the two drugs8 15 25 3e.
In â recent double-blind trial bâsed on the
quartitative oogram technique, rÃre also found
no signilicant difference in the efncacy of both
drugs administêred in a single dose, praziquån-
tel65 mg/kg ând oxamniquine 18 mg/kg12. Howe-
ver, contrary to thepreviously reported ñndings,
the achieved cure rates, 29Eø and 23Eo tesþec-
tively, were rather low. These divetgent results
can be explained by the unequal accu¡acy of
the methods apf,lied for parasitological evalua-
tion since, in the same t¡iâI, the coFespondent
cure rat€s according to stool examinations by
Kato-Katz were 92Eo and 86Ea, and by Hofüna¡,
Pons E¡ Janer 5070 for either drug. fn addition,
it has been demonstrat€d that â single dose of
praziquantel induces in practically alt patients
a complete interruption of the egg-laying capa-
city of the parasites during the ñrst four weeks
following the treatment. Thereafter, in non-cu-
red cases a sharp fau (83%) in the mean number
ofliving ova per gram of tissue is maintained.
Nevertheless, an explanation for the diver-
gence between the remarkable antischistosomal
activity observed experimentally and the f¡e-
quènt recurence rât€ we have found clinically
with a single dose administrâtion by means of
the oogram, requircs further considerations.
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INTRODUCTION
When schistosomes are exposed to prazi-
quantel they exibit an almost instanta¡eous te-
tanic contraction ofthe musculature3, ând rapid
structural damage to the syncytial tegument
sucb as vacuolization and surface blebbing6. 3r.
Tegumental injury (basal vacuolization) can be
induced by oxamniquine as well, but t,le lesion
becomes appârent only after hours or days2?
whilst n'ith praziquantel its onset is extremely
rapidæ 33. As early as 15 minutes after treating
mice, schistosomes were found contracted, para-
lysed and hanslocated from mesent€ric veins to
the liver and their tegument had developed typi-
cal lesions'e. In vitro exposure to 30 r¿glml for
60 minutes resulted in severe injurya. Evidence
fo¡ the râpidity ofpraziquantel action was equa-
Uy denoted by tlle reduction of 63% in the titer
of circulating v!'orm antigen ?2 hours following
tlle treatmentof mice infectedwith S. mansoni{.
Nonetheless, using sub-curative doses in mi-
ce theworms recovered and seemed to be almost
normal within three days, although the iDitial
appealence of the tegumental lesion was indis-
tinghishable f¡om that câused by a cu¡ative do-
se23.3?. This indicarcs that complete recovery
from the drug effect may take more than 24
hou¡s. Actually, observations in mice revealled
tñat on the 4th day subsequent to a si¡gle sub-
curative dose, S: mansoni have either recovered
or were dying in the liverr 30. Thus, a ce¡tain
degree ofinjury or of drug exposure can be tole-
rated by the pårasites and can be repaired, but
if the limit ofsuch repairing capacity is exceeded
then irreversible fatal damage occurss-
In fact, tegumental vacuolization itselfis not
lethal to schistosomes since parasites in mice
have recovered completely within 3 days after
a su¡-curative dose. Deâth of worms occurred
as soon âs t,he injury became severe enoughz.
In this circumstance, neutrophils aDd eosino-
Þhils were seen attached to the schistosome sur-
face alreådy 4 hours aft€r the drug administration.
Soon afterwards the worms became flxed to the
wâlls of blood vessels by ñbroblasts. Invasion
of schistosome's body by phagocyte cells was
in frtll progress 14 hours post-tteatment leading
to the lysis of the f,arasite tissues with¡n ? days.
Finally, the dead worms had disinteg¡ated ra-
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pidly, enclosed in a granulomatous reaction v/i-
tllin two weeks after therapy2e. The ¡apid aggre
gation of granulocytes around drug-affected pa-
rasites insinuates that immunological processes
may be involvedr. Indeed, exposure of previously
disguised S. mansoni antigens as a result ofcon-
tact with praziquantel has happened in vitrore.
The drugengenders membrane i¡stability which
exposes antigenic determinants leading granu-
locytes to congregate onto the worm. The partial
deshuction of the tegument opens doors for en
try ofphagocytic cells that then lyse the schisto-
some tissuesr. In addition, the release of antige-
nic component from injuried parasite tegument
may not only sensitize the host butpossibly con-
fer some degree ofresistance to subsequentlein-
fection{.
Consequently, the main question rests in the
deñnition of the optimal praziquantel concen-
tration and duration of exposure in vivo,
v¿hich is necessary to inflict treversible fatal da-
mage to the worms.
In vitro, experiments have revealed that
n'ith concentrations of 3.2 x 10-6M to 3.2 x t0-4M
of praziquantel the observed iniury to the para-
sites was â timefunction ofexposure to the drug,
râther than ofits concentration4 s 6. Apparently,
the antischistosomal efrect of prazÍquantel is not
so entirely ¡elated to the absolute height of its
mâximal plasma level as to the length of expo-
sure to the drug'. Praziquantel at a concentra-
tion of 0.6 ,¡M produces a good chemothera-
peutical effect, provided that the total period
ofexposure ranges from 6 to l0 hours'z.
In animals and man alike, following a¡ oral
intake,thedrugreaching theliverviaportâlvein
is extensively metâbolized at a fâst rate so that
within t houronly 5 to 7% are stiU unmetabolized
praziquantel (the biologically active principle)
and its half-life is just 90 minutesæ. This first-
pass effect, which varies from individual to indi-
vidual, is more effective in smaller doses than
in lâ¡ger onesæ. Peak serum concentration ofun-
changed praziquantel, 4.1 t¿M, is reached in
about 2 hours and may prevail for approximately
4 hours after an oml dose of 50 mg/]Kq.,2oEo (0 8
,,M) being the active protein unbound fractionæ.
Therefore. the effectively available drug is
only a small percentage ofthe total administered
dose and lasts for â relatively short time.
Actuâlly, the same dose has been more effec-
tive in killing late râther than early develop-
mentâl stâges ofS, mansoni in vivo, but no such
difference in susceptibility was observed in vitrc.
This apparent resistance might result from these
immature forms found in the peripheral syste-
mic circulation being exposed to lower concen-
trations of prâziquantel thân the mature para-
sites located in the liyer and mesenteric veins".
The drug bioavailability, however, can be im-
proved by changing its dosage schedule.In mice
the total amount of praziquantel required per
os to produce a reduction of957¿ in the number
of parasites could be decreased by more than
70% by administering multiple doses (10 x 18.5
mg/kg) instead of only one (1 x 685 mg/kg)r8. A
single oral dose of 50 mg/kg diminished tl1e num-
ber of S. mansoni id mice by 127o whilst 5 doses
given at dâilyintervâts killed 827, ofthe wormsrs.
Based upon: (a) our previous therapeutical
trialuin which ithâs been proven, through se¡ial
rectal mucosâ biopsies, thât a single dose ofpra-
ziquantel leads to a marked decrease of the
worm burden in human S, mansoni infection;
(b) the experimental evidence that, depending
on the concentration and time ofexposurc, this
drug is able to cause the deâth of this pansite;
we have designed the present clinical tria.l to
investigate whether dose regimens other than
a single day treatment would yield htgher cure
rates.
PATIENTS AND METHODS
Children, etderly patients, pregnant or lacfa-
ting women, and those cases having concomi-
tant acute or serious chronic diseases, severe
ânemiâ or nutritional deficiency, cardiac, pul-
monar, hepât¡c or renal insufficiency, were ex-
cluded from the trial.
A. total of80 patients ftee from previous speci-
fic tlrerapy, 4lEø male and 597¿ female, ftom 15
to 55 yea¡s old with â mean age of 2?, weighing
57.8 kg in the average, qrith chronic intestinal
(64%) or hepatointesti¡af (367o) schistosomiasis
mansoni hâd voluntarity been enrolled in t¡e trial.
All of them wer€ living in Belo Horizont€, state
capital of Minas Gerais, away from endemic areas.
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The worm burden âs measured by the num-
ber of viâble eggs per grâm of tissue taken by
rectal mucosa biopsy rânged from 1,1?3 up til
12,8?5 with a meân of3,410 and â median of3,025.
Nine percent had more than 5,000, 45Eo lrom
3,001 to 5,000, 32Eo from 2,001 to 3,000 and 1470
from 1,001 to 2,000. These figures shape a skewed
distribution curve with most of the pâtients, as
it tr'ould be expected, lodging a u¡orm burden
lower than the mean. Consequently, non-para-
metric tests (chi-square and Fisher exact proba
bility iests, were applied for the statisticat analy-
sis ofthe results.
the patients were treated ât an out-patient
clinic and instructed not to get in touch with
TABLE I
Distrlbution of patlents wiih schistosomiasis mânsonl in accordance with the alose regimen ofpraziquâniel, sex, age, body
any focus of schistosoma infection at least du-
ring the six-month period subsequent to the the-
rapy. Following a randomized distribution they
v/ere allocated into four groups having ân equal
number ofcases and were then treated \Ã'ith difre-
rent dose regimens: 60 mg/kg fo¡ 1 day; 60 mg/kg
dâily for 2 days; 60 mg/kg daily for 3 days; and
30 mg/kg dâily for 6 days. As shown in Tabte
I the four groups were homogeneous in regard
to the relevant fâctors that could influence the
therapeutical response, particularly the age ran-
ge ofthe patients and the intensity oftheir worm
burden.
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Praziquântel was presented in tablet folm
containing 300 mg. The total daity dose was âd-
ministered per os, in the morning, divided into
two intakes 4 hours âpart, under nurses' close
supervision. During the dâys of treatment the
pa¿ients remained under clinical observation for
a few hours after the drug administ¡ation in or-
der to look for any occurrence of adverse reac-
tions.
PrioÌ to the therapy all patients underwent
a thorough physical examination and were sub-
mitted to rectal mucosa biopsy in order to have
a quântitâtive oogram perfo¡mede rr, âs well as,
to stool examinations by both the qualitative
















































Kato-Katz2a methods. A kit (vermi-fec') from
Boehringer Mannheim vras used for the latter
examination and for each !,atient the result was
expressed by the ârithmeticmean ofthree slides.
All these parasitological examinations were re-
peated on the same day, at the end of the lst.,
2nd.,4th. and 6th. month post-treatment.
&ESULTS
The occurrence of untoward effects is de-
monstrated in Table II. The best tolerated dose
regimen wâs 30 mg/kg daily for 6 days whereas
the higher incidence of complaints was assocta-
ted with tlte administratior of 60 mglkg daily
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refering to: total incidence of side effecÙs (40%
vs. 807¿); dizziness (157¿ vs. 657o): ând nausea
(15% vs.55Eo). wete significantly (p < 0.05) ìower
with tbeformer dosage. The inverse holding true
for light severity oi symptoms (67% vs.32Ea). On
the other hând, there was neither any signifrcant















amongst the four groups nor any occurrence of
serious adverse drug reaction. With the m4jority
of the patients the side-effects aÞpeared within
the first four hours (987a) subsequent to the
drug intake, did not last longer than 12 hours














The assessment of therapeutical efücacy in
accordance with the quantitative oogram tech-
nique, as shov/n in Table III, reveâled the follo-
\Ã'ing cure rates, i. e., no single viable S. mansoni
egg in all rectal mucosa biopsies performed
during the 6-month parasitological follow up;
25Ea wit}r60 1'rg,l]r.g, for I day; 6070 with 60 mg/kg
daily ior 2 days;89.5Eo with 60 mg/kg daily for
3 days; ând 90% ysith 30 mg/kg dâily for 6 days.
The lâst two regimens did not differ one ftom
the other, but there had þeen a highly significaÌt
































Therapeutical emcacy of direlent dose regimens of prâziquantel accordlng to the quântiiative oogrâm Þe¡formed l, 2, 4 and




















for 2 days (p < 0.01) or 60 mg/kg for I day (p
< 0.001). Inôlusively these two last dosages also
differed significantly (p < 0.01) one from
the other. Furthermore, a marked reduction in
the median number of viable eggs per gram of
tissue in non-cured patients was observed in all
four groups. However, this reduction was more
noticeable with eitlìer 60 mg/kg dâily for 3 days
(minus 8?%) or 30 mg/kg daily for 6 days (minus




vlâble egggg of tissue
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Considering the cure râtes in relation to the
stool examinations by Hofünan, pons & Janer
and Kato-Katz methods, the corresponding figu-
res were: 397. and 89% with 60 mg/kg for 1 day;
SOqa and lOÙVa with 60 mg/ke daily for 2 days;
t00% and I00% with 60 mg/kg daily for 3 days:
TABLE IV
compÙison of curc rates âttainecl accordi¡g to the quântitahve oogram and stool exâmrnârrons by Hotfmar¡. I,ons & Jâner





95% and 100./. with 30 mg/kg dâity for 6 days.
When confronted with the oogram fìndings these
percentages aÌe quite dive¡gent particulùly the
data pertaining to Kâto-Katz as seen in Table













curacy. In fact, when the number of viable eggs
per gram of tissue fell below 2,000 the difference
(207o)in the positivity by Hoffrnân, pons & Janer
in relation to the oogram became statistÍcally
signiñcânt (p < 0.01). Moreover, the difference
(437¿) betv/een the positivity of Kato-Kåtz and
Hofünan, Pons & Janer already tu¡ned signifi_
cative when that number was inferior to 5,000.
These results are displayed in Table V and cra_
phic 2.
TABLE V
Colre¡åtrcn bctween rhe quâniiLative ooelam 6¡dhgs â¡d rhepositivity of sl.ool examinâtions by Hoffman. pons & Jâner
rHPJr and Kato-Katz rK.Kr methods





30 ms kg dâily
6 dãvs
Graphic I - Correlârion between ihe cure rãt€s of var¡able
doses ofprâziqÌ¡ånteÌ and diffeæn¿ pùas¡tological methods (¡
oogmrn, EHoffman, Pons & Jã¡e¡, lllKato-Kaiz).
r ne orscrepancy amongst the three parasi








P.raziquantel, a novel schistosomicÍdal
agent which nowadays is regarded as the first
choice medication for human schistosomiasis22.
21 33, has proven acco¡ding to the quantitative
oogram technique, to be highly etï¡catious in S.
mânsoni infection if used in an adeouate dose
¡egrmen.
In this trial, n'hen administering 60 mglkg
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it rose up to 9070 when the same daily dose was
taken for 3 consecuüve days. ParâUelly, t¡ere
had been a corresponding downfâ-ll of 64% and
877o in the mediân nr¡mber of S. mansoni ova
per gram of feces in non cured patients, conñr-
ming both the superiorefncacy ofthe latter dosa-
ge ând the sensitivity of the aþplied parasito-
logical methodology.
lung fluke, 75 mg/kg daily tahen during 1,2 or
3 days ensued cure rates of nEo,86Eo and 1007¿,
resPectively.
The reason for attâining pârasitological cure
in somepâtients withjust asingle day treatment
urhereas in others, solely if the drug adminis-
t¡âtion is prolonged for two or more days, most
probably relies on the distinct patterns ofindivi,
duâl pharmacokinetics. Those who convert pra-
ziquantel quickly and extensively into hydroxy-
lated and conjugated metabolites, that are inac-
tive or considerably less potent, will lequire hi-
gher doses and/or lengthned therapeutical cout-
ses than those who do not eliminate the drug
ftom plasmâ so efficiently. In this context, with
a single dose of 30 mg/kg a relatively high cure
rate (76.770) has been ob¿ained in hepatosplenic
schistosomiasis mansonir0 in comparison to the
quite lov/ figurc (33.37a) attained in i¡testinâl or
hepatointestinâl cases35, using the sâme pârâsi-
tological control ofcure (Kato-Katz stool exami-
nation). Perhaf,s, patients presenting hepatos-
plenic forms metabolize p¡aziqua¡tel at a slower
pace or the drug by passes the liver via pottosys-
temic shunts allosring higher plâsma concentra-
tions of the active flrinciple for longer periods
of time.
Certainly, as it v¡as demonstrated in vivo,
the antiparasitic efñcacy of praziquantel against
S. mansoni is due to r'ts âbility to produce tegu-
mental damage, an effect thât depends on the
drug concentration a¡d on the duration of the
parasite exposure to it{{. Both are a function of
the peak level and time course ofunmetabolized
praáquantel in the serum which arc known to
vary greatly ftom patient to patient'8 42. There-
fore, ideally an individual dose regimen should
be established for eve¡y pâtient based on the
monitoring of the drug serum concentÌàt¡on, þut
in practice this is unfeasible. Possibly, a simple
way to secure a cure rate very close to 1007¿ in
all cåse would have to consist of augmenting the
total dose up to 240 mg/kg (either 40 mgkg daily
for 6 days or80 mg/kg daily for S days). Actually,
total doses of 1,000 mg/kg or even higher (100
mg/kg daily during l0 days7, 50 mg/kg daily du-
ring 3 week$r, ?5 mg/kg daily during 15 days?)
have been v¡ell tolerated by patients with neurc-
cysticercosis.
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Graphic 2 - Corelâtion between ihe quantibative oog¡âm Í¡
dings ånd the positivity of the stool exùblnations by Ëoffr¡an,
Pons & Jarer (@) âÀd Kato-Katz (a) methods.
In tl¡e treatment of other human tremato-
diases with praziquantel, analogous therapeu-
ticâl responses s¡ere reported'r: in Opisthorchis
viver¡in¡ infections cu¡e rates of447¿ or 887o we-
re achieved with 1 or 2 days administration of
25 mg/kg daily and with 30 mg/kg daily for 3
days 91qa was reached: with infections caused
by Clonorchis sinensis, anoths liver fluke, 50
mg/kg dàily yielded, 47qo cure rat€ if given for
I day but 807¿ if given for 2 days, yet more ?5
mg/kg for I dây resulted in 817¿ cure rate and
1007¿ when tåis daily dose wâs extended for 2
days; in Paragon¡mus westemani infections, a
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Another relevant aspect to be considered is
the disparity amongst the ¡esults accomplished
wÍth the different procedures emptoyed for as-
sessment of parasitologicâl cute. In fact, the ac_
curacy of the stool examination methods have
varied in direct correlation with the number of
viable ova per gram of tissue in the oogram: be
low 5,000 the Kato-Kâtz alreadyshowed a signifi_
c tt lower sensitivity in comparison to the lloff_
man, Pons & Janer, which for its turn was signifî_
cantly ir¡ferior to the oogrâm when that number
was less than 2,000. In connection to this, we
hâve already commented on similar findings
achieved in a previous clinicaì trialrr. Likewise,
other investigâtors have demonstrated the supe
riority of the rectaÌ mucosa biopsy in proving
the presence of schistosoma ova in respect to
stool ñltration and MIF concentlation methods.
which stitl yield more reliâble results than a di.
rect fecal smeatl8. Furthermore, they also hâve
pointed out that the positivity offecal examinâ-
tions diminishes in direct conelation with the
decrease in the number ofyiâble eggs per 20 mm2
of tissue in the biopsyrs.
In conclusion, it has been proven that a 902¿
cure rate can be attained in schistosomiasis
mansoni with praziquântel when administerins
either 60 mg/kg daily during 3 days or 30 mg/k;
daily duúng 6 days. The former dosage is more
convenient but the latter has been associated
with mildet and lower incidence ofuntoward ef_
fects. The ideal dose regimen should be hxed
individualy by vi¡tue of the va¡iable intestinal
absorption rate, extent of hepatic metaboliza_
tion and plasma protei¡-binding capacity, main
factors that influence .the setum concentration
of the unchanged prâziquantel ând its hâlf_life.
However, since it is unfeasible to establish a spe_
cific dosage foÌ€yery pâtient, perhâps the admi_
nist¡ation of a total dose of 240 mg/kg clivided
into 3 or 6 days would lead to tOOEo ctjre rate.
Finally, ithas been confirmed that the quan_
titative oog¡am technique is the most accurate
method for assessing the therapeutical efñcâcy
of antischistosomal agents in mansoni schisto_
somlasis so that it should be apptied at the ear_
liest phases of the clhicâlstudy ofâlt new d¡uss.
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Âvaliaçáo têrapêutica de diferen¿es esquemas
posológicos do ptaziquantel na esquistossomo.
se mansônica, baseada na técnica do oograma
quantitativo,
Uma pesquisa clinica compreendendo g0 pa_
cientes de ambos os sexos, de t5 a 55 anos de
idade, portadores de esquistossomose mansôni_
ca crônica, formas intestinal ou hepatintesti-
nal, foi efetivadâ para avaliâr a ef,icáciâ do prazi_
quântel em diferentes esquemas posológicos.
Os pacientes foram distribuÍdos aleatoria_
mente em quatro grupos, com igual número d.e
casos, sendo tratados com uma das seguintes
dosagens: 60 mg/kg em um dia, 60 mg/kg diários
por dois diâs, 60 mg/kg diários por três dias e
30 mg/kg diários por seis dias.
A âvaliaçáo dâ curâ parâsitológica baseou_
se nâ técnica do oograma quan¿itativo mediante
biópsias da mucosa retal, realizadas antes, bem
como um, dois, quatro e seis meses após o trâta
mento. Concomitantemente, efetuaram_se exâ
mes de fezes segundo os metódos qualitativo de
Hoffrnan, Pons & Janer e quantitativo de Kato-
Kaïã.
A melhor tolerabilidade foi verifÌcadâ com
30 mg/kg diários durante seis diâs, enquanto a
maior incidéncia de efeitos colaterais. em espe_
cial tonturâ e náusea, ocor.reu com 60 mg/kg cliá_
rios durante três dias. Nenhuma reaçáo âdversa
grave foi observada com o medicamento.
Alcançaram-se os seguintes Índices de curâ:
25% comíOmg/kgem um dia;60% com 60mg/kg
diáriospordois dias;89,570 com 60 mg/kg diários
por três dias e 90Ea com 30 mg/ke diárìos por
seis dias. Pâralelamente houve uma queda de,
respec tivamente, 6 4Ea , 73Ea , A7 Eo e 84% no núm e_
ro mediano de ovos viáveis de S. mansoni por
grama de tecido. Assim, constatou_se uma corre_
laçáo dheta entre dose e efeito_
Os coffespondentes Índices de cura, segun_
do os exames de fezes, foram ZgEô, AOEÒ, IOOEa
e 957o com o método de lloffman, pons & Janer
e com o de Kato-K atz qgEø , tOOEo , IOO%. e t\OEo .
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A discrepância encontrada nos resultados
-'ntre os três métodos parâsitológicos decorre dâ
desigualdade nâ precisão dos mesmos. euando
o número de ovos viáveis por grama de tecido
caiu abaixo de 5000, a diferença no percentual
de achados falso negativos entre Hoftnann, pons
& J anet (28Ea) eKalo-Katz(80Eal tornou-se signi-
ñcativa. Quando esse número baixou parâ me
nos de 2000, a percentagem de resultâdos faìso
negativos encontrâda com Hoffman, pons & Ja
ner (49%) tâmbém pâssou a ser significâtiva em
relâçáo ao oograma.
Em conclusáo, ficou provâdo que o prazi-
quantel é altamente ef\caz na infecçáo pelo S.
mansoni, Administrado nâ dose total de 180 mg/.
kg, dividida em três ou seis dias, o praziquântel
proporcionou 907¿ de cura. Provavelmente, po-
deria atingir 1007o se a dose total fosse aumen-
tadapara 240 mg/kg. Ademais, confirmou-se que
o oogramâ quanfitativo consiste no método
mâis fidedigno para âyaliar a eficácia terâpéu-
tica de novas drogas na esquistossomose man-
sônica.
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